This opinion piece, authored by Iqra Ather and K. Madan Gopal who work at the National Health Systems Resource Centre (NHSRC), explores the promise of biosimilars in making life-saving treatments—such as those for cancer, diabetes, or autoimmune diseases—accessible to all. As global healthcare systems seek cost-effective solutions, the authors examine whether India can emerge as a leading hub for affordable biosimilar production.
